Progenra Announces the Availability of its UbiPro™ Drug Discovery Platform for Licensing

Progenra, Inc., announced today that their UbiPro™ Drug Discovery Platform is available for licensing to partners interested in discovering drugs that modify the ubiquitin-proteasome pathway.
By: Marc Hixson
 
Aug. 8, 2011 - PRLog -- MALVERN, PA – Progenra, Inc., announced today that their UbiPro™ Drug Discovery Platform is available for licensing to partners interested in discovering drugs that modify the ubiquitin-proteasome pathway.  The UbiPro™ Drug Discovery Platform encompasses all of Progenra’s current and future proprietary technology discoveries used for identifying novel modulators of deubiquitylase and E3 ubiquitin ligases.

Progenra’s UbiPro™ Drug Discovery Platform offers the company’s partners several advantages over current technologies.  Those include:

•   Identification of compounds not detectable using traditional “off-the-shelf” assays and reagents
•   A proven technology for precluding the identification of reactive “nuisance” screening hits
•   Industry leading panel of deubiquitylase and E3 ligases to be used for profiling and selectivity
•   Selective and semi-selective deubiquitylase and E3 ligase inhibitors as molecular probes
•   A comprehensive vs. singular approach towards the identification of novel modulators
•   Best commercial platform available that covers both deubiquitylase and E3 Ligase drug discovery
•   Ability to instantly advance a partner’s deubiquitylase or E3 Ligase discovery program

“Years of study have taught us that commercially available generic deubiquitylase and E3 ligase assays are not suitable for every deubiquitylase or ligase. Here at Progenra we develop and continue to refine a suite of assays, one which is optimal for each ubiquitin pathway enzyme,” said Michael Mattern, COO of Progenra.  “For this reason, access to Progenra’s platform confers to our partners the ability to successfully screen the broadest possible range of therapeutically relevant ubiquitin targets.”

To date, Progenra has successfully partnered its technology and know-how with academic institutions and pharmaceutical companies worldwide.

About Progenra, Inc.

Founded in 2002, Progenra is focused on discovery and development of medicines by targeting the ubiquitin pathway, which plays a role in numerous therapeutic areas.  Progenra believes that by selectively targeting specific enzymes within this pathway, the degradation of a specific protein or limited family of proteins can be modified, thus avoiding issues which occur if one blocks all protein degradation with the proteasome, thus limiting the side effects. To date Progenra has identified compounds that are in pre-clinical development for a variety of diseases. The company’s intellectual property portfolio underscores Progenra’s commitment to both its technology platform development and drug discovery in the ubiquitin field.

For further information please contact:
Marc Hixson
Progenra Inc.
hixson@progenra.com
215.834.3583
http://www.progenra.com
End
Source:Marc Hixson
Email:***@progenra.com Email Verified
Tags:Pharmaceutical, Biotech, Ubiquitin, Drug Discovery, Progenra
Industry:Biotech
Location:United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Progenra, Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share